SK pharmteco partners with Prozomix to expand biocatalysis in drug manufacturing. Discover what this means for greener APIs and global CDMO strategy.
In the decades-long war against disease, pharmaceutical companies have learned to build drugs like locksmiths—designing compounds that fit neatly into molecular pockets, disabling enzymes and receptors with surgical precision. But not every biological lock comes with a keyhole. Protein–protein interactions, or PPIs, often involve broad, flat, and shifting surfaces that refuse to conform to conventional